Modeling the Effects of Clinical Breast Examination: Estimating Benefits and Harms From 2 Indian RCTs

ABSTRACT 73% of women dying from breast cancer (BC) come from low‐ or middle‐income countries. These countries often do not have national mammography screening programmes. A less resource‐demanding option is screening through clinical breast examination (CBE). As limited evidence exists for its effectiveness, two CBE trials have been conducted in India to assess efficacy with different designs and results. This study aims to model the natural history of BC and the performance of CBE using data from both trials to estimate the long‐term effects of CBE and alternative screening scenarios. We used the well‐established microsimulation model MISCAN‐Fadia and utilized region‐specific incidence, trial‐specific inputs (such as screening interval, screening ages, attendance, and treatment regimens) to construct trial‐specific models. We reported outcomes for both Trivandrum and Mumbai models with respectively 14 and 20 years follow‐up time, as well as lifetime follow‐up. The stage distribution in both trials was accurately reproduced by the models. Our models estimated BC mortality reductions between 5% and 6% for the Indian CBE trials, which were higher than reported by the CBE Trivandrum trial and lower than the Mumbai trial. When assuming 100% attendance with triennial screening between age 30–69 and a lifetime follow‐up, model results showed a BC mortality reduction of 12%. Women in resource‐limited countries may benefit from CBE screening, which given resources should not be seen as second‐best. Screening with CBE in a broad age range of 30–69 can lead to reductions in BC mortality.

Authors

Institutions

Publication Details

Journal
International Journal of Cancer
Published
2026-11-14
DOI
https://doi.org/10.1002/ijc.70827
Primary Topic
Global Cancer Incidence and Screening
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modeling the Effects of Clinical Breast Examination: Estimating Benefits and Harms From 2 Indian RCTs

Partha Sarathi Basu, Eric Lucas, Richard Muwonge, Harry J. de Koning et al.
International Journal of Cancer
Global Cancer Incidence and Screening
article

Modeling the Effects of Clinical Breast Examination: Estimating Benefits and Harms From 2 Indian RCTs

Partha Sarathi Basu, Eric Lucas, Richard Muwonge, Harry J. de Koning, Nicolien T. van Ravesteyn, Sarocha Chootipongchaivat, Lindy Kregting
article en

Abstract

ABSTRACT 73% of women dying from breast cancer (BC) come from low‐ or middle‐income countries. These countries often do not have national mammography screening programmes. A less resource‐demanding option is screening through clinical breast examination (CBE). As limited evidence exists for its effectiveness, two CBE trials have been conducted in India to assess efficacy with different designs and results. This study aims to model the natural history of BC and the performance of CBE using data from both trials to estimate the long‐term effects of CBE and alternative screening scenarios. We used the well‐established microsimulation model MISCAN‐Fadia and utilized region‐specific incidence, trial‐specific inputs (such as screening interval, screening ages, attendance, and treatment regimens) to construct trial‐specific models. We reported outcomes for both Trivandrum and Mumbai models with respectively 14 and 20 years follow‐up time, as well as lifetime follow‐up. The stage distribution in both trials was accurately reproduced by the models. Our models estimated BC mortality reductions between 5% and 6% for the Indian CBE trials, which were higher than reported by the CBE Trivandrum trial and lower than the Mumbai trial. When assuming 100% attendance with triennial screening between age 30–69 and a lifetime follow‐up, model results showed a BC mortality reduction of 12%. Women in resource‐limited countries may benefit from CBE screening, which given resources should not be seen as second‐best. Screening with CBE in a broad age range of 30–69 can lead to reductions in BC mortality.

International Journal of Cancer
Erasmus MC (NL), Radboud University Medical Center (NL), Centre international de recherche sur le cancer (FR)
Global Cancer Incidence and Screening
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon